when did glp 1 agonists come out Evolution of GLP‐1 Receptor for Diabetes Treatment Timeline of GLP-1 discovery and
Description
Semaglutide and the risk of diabetic retinopathy-current perspective
The authors compared changes in glycemic control and BMD with and without conversion from DPP-4 inhibitor to GLP-1 receptor agonist for 3 years and observed that patients who switched to the latter had greater decline in lumbar BMD than controls regardless of weight loss [12, 61]
Researchers running high-dose protocols that deplete vials quickly face less stability concern, but those on lower doses like 1mg or 2mg may find that a single vial lasts close to the stability window, making careful date tracking essential
A pill containing 25 mg of semaglutide delivers results comparable to Novo Nordisks 2.4 mg injectable, according to the press release
Weight loss may be slow initially, and you usually see the benefits a few weeks after being on these medications when your dose is increased
